Trials / Terminated
TerminatedNCT04766476
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-963272 compared to placebo in participants with nonalcoholic fatty liver disease (NAFLD) and high probability of advanced fibrosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-963272 | Specified dose on specified days |
| OTHER | Placebo matching BMS-963272 | Specified dose on specified days |
Timeline
- Start date
- 2021-02-24
- Primary completion
- 2021-08-12
- Completion
- 2021-08-12
- First posted
- 2021-02-23
- Last updated
- 2022-06-09
Locations
19 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04766476. Inclusion in this directory is not an endorsement.